Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Lexicon Pharmaceuticals, Inc.    LXRX

 SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2017 94,1 M
EBIT 2017 -160 M
Net income 2017 -154 M
Finance 2017 8,75 M
Yield 2017 -
Sales 2018 172 M
EBIT 2018 -65,8 M
Net income 2018 -78,3 M
Finance 2018 2,00 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 19,0x
EV / Sales2018 10,5x
Capitalization 1 797 M
More Financials
Company
Lexicon Pharmaceuticals, Inc. operates as a biopharmaceutical company which focuses on the development of breakthrough treatments for human disease.It has multiple programs in clinical development for diabetes, irritable bowel syndrome, carcinoid syndrome and other indications.The company was... 
More about the company
Surperformance© ratings of Lexicon Pharmaceuticals, I
Trading Rating : Investor Rating :
More Ratings
Latest news on LEXICON PHARMACEUTICALS, I
07/07 LEXICON PHARMACEUTICALS, INC. (NASDA : LXRX) Files An 8-K Entry into a Material ..
07/07 LEXICON PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement (form..
06/30 VALERITAS : U.S. Patents Awarded to Inventors in New Jersey (June 30)
06/29 LEXICON PHARMACEUTICALS : NCCN Guidelines For Neuroendocrine Tumors Include XERM..
06/23 LEXICON PHARMACEUTICALS : U.S. Patents Awarded to Inventors in Connecticut (June..
06/20 LEXICON PHARMACEUTICALS : Pharma (LXRX) Announces XERMELO In Combination With So..
06/15 LEXICON PHARMACEUTICALS : Reports Positive Top-Line Results In Phase 3 inTandem3..
06/15 LEXICON PHARMACEUTICALS : To Present New Clinical Data At 77th American Diabetes..
06/14 LEXICON PHARMACEUTICALS : Pharma Goes Three For Three With Sotagliflozin Data
06/12 LEXICON PHARMACEUTICALS, INC. : Corporate News Blog - Lexicon Pharma's Diabetes ..
More news
Sector news : Bio Therapeutic Drugs
07/18 JOHNSON & JOHNSON : J&J sees sales growth in near-term; raises 2017 profit forec..
07/18 JOHNSON & JOHNSON : J&J sees sales growth in near-term; raises 2017 profit forec..
07/12 FDA panel backs Novartis' pioneering new cancer gene therapy
06/23DJOne of the Last Untapped Blockbuster Diseases? Drug Companies Race to Find a ..
06/20 Novartis eye drug works with fewer injections than rival
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
2015 SEEKING ALPHA'S BIOTECH WEEKLY : A Gilead Victory, Celladon Crumbles, And More
2015 Lexicon Undervalued As It Approaches A Major Event
2015 Lexicon Pharmaceuticals' (LXRX) CEO Lonnel Coats on Q1 2015 Results - Earning..
2015 Lexicon Pharmaceuticals EPS in-line, beats on revenue
2015 Lexicon Pharmaceuticals - A Diamond In The Rough?
Chart LEXICON PHARMACEUTICALS, I
Duration : Period :
Lexicon Pharmaceuticals, I Technical Analysis Chart | LXRX | US5288721047 | 4-Traders
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 26,6 $
Spread / Average Target 56%
EPS Revisions
Managers
NameTitle
Lonnel Coats President, Chief Executive Officer & Director
Raymond Debbane Chairman
Jeffrey L. Wade CFO, EVP-Corporate & Administrative Affairs
Pablo Lapuerta Chief Medical Officer & EVP-Clinical Development
Frank P. Palantoni Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
LEXICON PHARMACEUTICALS, INC.12.10%1 797
AMGEN23.84%133 151
CELGENE CORPORATION19.08%107 629
GILEAD SCIENCES3.00%97 208
REGENERON PHARMACEUTICALS40.54%55 401
VERTEX PHARMACEUTICALS121.49%41 373